Export 37 results:
Author Title Type [ Year(Desc)]
Filters: Author is Hill, Heather  [Clear All Filters]
2014
F. M. Munoz, Weisman, L. E., Read, J. S., Siberry, G., Kotloff, K., Friedman, J., Higgins, R. D., Hill, H., Seifert, H., and Nesin, M., Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy., Clin Infect Dis, vol. 59 Suppl 7, pp. S415-27, 2014.
K. L. Kotloff, Halasa, N. B., Harrison, C. J., Englund, J. A., Walter, E. B., King, J. C., C Creech, B., Healy, S. A., Dolor, R. J., Stephens, I., Edwards, K. M., Noah, D. L., Hill, H., and Wolff, M., Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children., Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
R. L. Atmar, Opekun, A. R., Gilger, M. A., Estes, M. K., Crawford, S. E., Neill, F. H., Ramani, S., Hill, H., Ferreira, J., and Graham, D. Y., Determination of the 50% human infectious dose for Norwalk virus., J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M. El, Spearman, P., Rouphael, N., Rudge, T. L., Hill, H., and Goll, J. B., Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults., Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals., Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
2015
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects., Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations., Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age., J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.